The PIK3CA gene is mutated in nearly 40% of women with HR+/HER2- metastatic breast cancer and abnormal signaling in the PIK3CA pathway is related to tumorigenesis, progression, and therapeutic ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has granted ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive results from the Phase III INAVO120 study of the ...
Finding showed the inavolisib-based regimen reduced the risk of disease progression or death by 57% compared with palbociclib and fulvestrant alone. The Food and Drug Administration (FDA) has approved ...
New data underscore efficacy of Piqray, even in those patients with a short treatment duration on prior CDK4/6i or with ESR1 mutations, biomarkers of endocrine resistance[1-5] Recent guideline updates ...
The outlook for someone with PIK3CA-related overgrowth spectrum (PROS) depends on factors that vary from person to person. Early intervention and treatment can improve the outlook and prevent ...
The designation is based on Phase III INAVO120 results, showing the inavolisib-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback